Skip to content
thestock.space

3B Blackbio Dx (3BBLACKBIO) had a P/E of 19.5× on 6 Nov 2026, below the industry P/E of 49.1×, and the shares are 26% below their 52-week high. It earns ROCE of 23% and ROE of 20%, and sales and net profit grew 32% and 32% a year over 3 years. It has almost no debt, and its dividend yield is 0.4%. It is a small-cap company with a market cap of ₹1,102 Cr, ranked 11th of 20 Biotechnology companies by market cap; the shares rose 14% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹1,315.80
Day high
₹1,325.00
Day low
₹1,270.00
Prev. close
₹1,309.10
Volume
12K

Health check

4 good · 1 fair · 1 to check
  • ReturnsAhead

    +14.0% over a year, better than 6 of 7 peers.

  • Price tagCheaper

    P/E 19.5 vs industry 49.1.

  • GrowthStrong

    Sales +31.9%, profit +32.2% a year over 3 years.

  • ProfitabilityStrong

    ROCE 22.6% vs peer median 16.7%.

  • Balance sheetFair

    Practically debt-free, Piotroski 5 of 9.

  • Red flags1 to check

    Quarterly profit down 24.3% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Biotechnology

19 listed peers. Screen the industry

Small cap

₹1,102 Cr, #11 of 20 in its industry by size.

Defensive

Beta 0.48 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹153 Cr · profit ₹56 Cr
Market cap
₹1,102 Cr
Small cap
P/E
19.5
Industry 49.1
Price to book
3.31
Peers 4.68
Dividend yield
0.38%
ROE
20.2%
Peers 14.3%
ROCE
22.6%
Peers 16.7%
Debt to equity
0.01
Debt ₹3.11 Cr
EPS (TTM)
₹65.81
Face value ₹10
OPM (TTM)
34.7%
Net margin 36.3%
Sales growth
+50.6%
Latest quarter vs a year ago
Profit growth
−24.3%
Latest quarter vs a year ago
Price to sales
7.20
EV/EBITDA 19.5

Strengths and risks

Strengths

  • Return on equity of 20.2%.
  • Return on capital employed of 22.6%.
  • Practically debt-free.
  • Quarterly sales up 50.6% on a year ago.
  • Net margin of 36.3%.

Risks to check

  • Quarterly profit down 24.3% on a year ago.

Derived automatically from reported figures. Not a recommendation.

About 3B Blackbio Dx

3B Blackbio Dx Limited manufactures and sells molecular diagnostic kits in India. The company designs, develops, manufactures and commercializes qPCR assays, rapid diagnostic tests, NGS-based diagnostic kits, digital PCR assays, and nucleic acid extraction solutions for reliable testing of patient samples, as well as offers oncology and hematology, antimicrobial resistance, infectious diseases, human genetics, extraction, and rapid antigen kits under the…

Headquarters
Bhopal
Employees
86
Sector
Healthcare
ISIN
INE994E01018
Website
3bblackbio.com

Price range

52 weeks

₹1,099.50₹1,740.00

Today

₹1,270.00₹1,325.00
Avg volume (3M)
20.1K
1-year return
plus 14.0%
From 52-week high
minus 26.2%

Peers · Biotechnology

Compare with peersScreen the whole industry
Company
BIOCONBiocon365.10plus 0.86%59,794122.51.732.8%1.0%20.5%15.3%−5.9%0.14%minus 4.9%
ANTHEMAnthem Biosciences915.55plus 0.22%51,59484.615.7426.8%20.4%41.4%26.2%15.4%0.22%plus 30.1%
ONESOURCEOnesource Specialty Pharma1,599.80plus 1.13%18,346–3.100.3%0.0%23.5%232.3%–0.00%minus 13.7%
CONCORDBIOConcord Biotech632.60minus 5.96%13,23647.46.4816.7%14.3%34.5%8.0%2.8%0.56%minus 7.5%
BLUEJETBlue Jet Healthcare553.80minus 3.91%9,60734.54.5224.0%19.9%31.4%9.4%15.7%0.21%minus 5.0%
SUPRIYASupriya Lifescience695.80minus 19.99%5,60028.24.6822.3%19.1%21.4%21.2%32.5%0.11%plus 9.2%
ZOTAZota Health Care1,231.10plus 1.01%4,264–6.82−7.3%−24.1%0.1%56.7%–0.08%minus 21.9%
3BBLACKBIO3B Blackbio Dx1,284.20minus 1.90%1,10219.53.3122.6%20.2%34.7%31.9%32.2%0.38%plus 14.0%
Median of 7 peers–0.22%13,23647.44.6816.7%14.3%23.5%21.2%15.4%0.14%−5.0%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
22.233.950.335.433.5
10.419.22926.925
11.814.721.38.58.5
53.2%43.5%42.4%24.0%25.4%
4.35.5610.16.1
000.10.10.1
0.30.60.43.91.3
15.919.626.814.613.2
20.3%23.4%16.4%33.1%32.1%
12.614.721.79.69.5
14.6717.5525.3211.4411.11

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+31.9%
Profit CAGR 3Y
+32.2%
EPS CAGR 3Y
+32.2%
ROE
20.2%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
61.874.196.5142
–+19.9%+30.1%+47.1%
32.341.146.181.6
29.53350.460.3
47.7%44.5%52.3%42.5%
4.16.78.718.4
0.20.10.10.2
0.91.11.15.1
2.85.96.13.6
35.344.36477
26.5%27.6%25.5%22.1%
25.932.747.759.9
–+26.2%+45.7%+25.7%
30.2737.4655.6669.94

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
8.68.68.68.6
185214260316
20.80.34.8
18.824.32748.8
214248296378
7.97.31921.9
0.1–––
91.7117–158
58.561.567.999.6
55.86220998.8
214248296378

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
20.32743.452.5
14.7−20.3−33.8−23.6
−5−3.6−3.2−0.5
3036.328.4
−2−0.5−0.9−25.5
18.326.442.527
−4.4−2.2−2.6−3.4

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 1.9% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you